Cingulate's ADHD drug stays in regulatory limbo as manufacturing fixes drag on

For Cingulate, the path to revenue from its lead ADHD asset still runs through a manufacturing fix. On 10 November 2026 the company said work on chemistry, manufacturing and controls (CMC) is continuing, and that a new submission to the US Food and Drug Administration for CTx-1301 will follow only once that work is done.

The FDA issued a Complete Response Letter on the product on 1 June 2026. It covered the new drug application for CTx-1301, which contains dexmethylphenidate hydrochloride. The company's chief executive discussed the company's response in a media interview. Cingulate says it intends to resubmit as promptly as practicable, but it has not committed to a date and cautioned that neither timing nor approval can be assured.

The chief executive also spoke about preparations for a commercial launch. The material available gives no detail on the scale or form of those preparations, and it does not describe the specific CMC shortcomings the agency raised, so the likely effect on launch timing or cost cannot be assessed.

By way of general context, a Complete Response Letter means the FDA has finished reviewing an application but cannot approve it as submitted. The sponsor must address the listed deficiencies and resubmit, after which the agency sets a fresh review goal date. Until Cingulate files, that clock cannot start.